evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/geneAliases/3,gene/geneAliases/4,gene/geneAliases/5,gene/geneAliases/6,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract,articles/10/pmid,articles/10/title,articles/10/journal,articles/10/pubDate,articles/10/volume,articles/10/issue,articles/10/pages,articles/10/authors,articles/10/elocationId,articles/10/link,articles/10/reference,articles/10/abstract
9409,GENE_SUMMARY,,"ABL1, a tyrosine kinase, is frequently altered by chromosomal translocations in leukemia.",,2017-04-10,,25,ABL1,"ABL proto-oncogene 1, non-receptor tyrosine kinase",True,ENST00000318560,NM_005157.4,v-abl,bcr/abl,JTK7,c-ABL1,c-ABL,ABL,p150,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9410,GENE_BACKGROUND,,"ABL1 (ABL proto-oncogene 1) is an ubiquitously expressed non-receptor tyrosine kinase. In response to a variety of signals, ABL signaling can result in cell proliferation or differentiation, survival or death, and cell retraction or migration depending on the stimulus and target (PMID: 7651539, 7512450). ABL is located both in the cytoplasm and nucleus and can be activated by growth factor receptors, DNA damage, and cellular kinases (PMID: 24421390, 1591775). Translocation between the BCR and ABL genes results in BCR-ABL, which is a constitutively activated oncogenic tyrosine kinase found in chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ ALL) (PMID: 3460176, 2825022). Alternative ABL1 translocations are also observed in myeloid disease (PMID: 9695962). The BCR-ABL fusion protein results in loss of auto-inhibition of ABL and instead, oligomerization leading to transphosphorylation and activation of the kinase (PMID: 8246975). Small molecule inhibitors of BCR-ABL, imatinib and dasatinib have been developed and FDA-approved for CML and Ph+ALL (PMID:11870241, 21931113). Mutations in the ABL kinase domain lead to resistance to these treatments and determine sensitivity to select agents (PMID: 15256671).",,2017-04-10,,25,ABL1,"ABL proto-oncogene 1, non-receptor tyrosine kinase",True,ENST00000318560,NM_005157.4,v-abl,bcr/abl,JTK7,c-ABL1,c-ABL,ABL,p150,False,1591775,c-abl has a sequence-specific enhancer binding activity.,Cell,0001-05-29,69,5,751-7,Dikstein R et al,,,0001-05-29,,3460176,The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.,"Science (New York, N.Y.)",0001-07-11,233,4760,212-4,Ben-Neriah Y et al,,,0001-07-11,,7512450,The nuclear tyrosine kinase c-Abl negatively regulates cell growth.,Cell,0001-04-08,77,True,121-31,Sawyers CL et al,,,0001-04-08,,9695962,Haemopoietic transformation by the TEL/ABL oncogene.,British journal of haematology,0001-07-01,102,2,475-85,Hannemann JR et al,,,0001-07-01,,11870241,Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.,The New England journal of medicine,2018-02-28T20:02:00,346,9,645-52,Kantarjian H et al,,,0001-02-28,,8246975,A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.,Molecular and cellular biology,0001-12-01,13,12,7587-95,McWhirter JR et al,,,0001-12-01,,21931113,Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.,Blood,2017-12-15T20:11:00,118,25,6521-8,Fo√† R et al,doi: 10.1182/blood-2011-05-351403,,0001-12-15,,7651539,Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents.,Nature,0001-08-31,376,6543,785-8,Kharbanda S et al,,,0001-08-31,,24421390,The capable ABL: what is its biological function?,Molecular and cellular biology,2018-04-01T20:14:00,34,7,1188-97,Wang JY,doi: 10.1128/MCB.01454-13,,0001-04-01,,2825022,A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia.,Nature,0001-11-26,330,6146,386-8,Fainstein E et al,,,0001-11-26,,15256671,Overriding imatinib resistance with a novel ABL kinase inhibitor.,"Science (New York, N.Y.)",2018-07-16T20:04:00,305,5682,399-401,Shah NP et al,,,2018-07-16T04:01:00,
